Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14857835 | 0.96 | CYP2B6 (0.44) | CYP2B6NOS1KMT2ANPC1RAB9A | |
| SCHEMBL1418289 | 0.94 | CYP2B6 (0.47) | CYP2B6NOS1KMT2ANPC1RAB9A | |
| SCHEMBL5141170 | 0.91 | — | — | |
| SCHEMBL25741022 | 0.87 | KMT2A (0.34) | CYP2B6NOS1KMT2AFDPSPRCP | |
| SCHEMBL25741934 | 0.86 | NOS1 (0.33) | CYP2B6NOS1KMT2AFDPSPRCP | |
| SCHEMBL25740904 | 0.84 | KMT2A (0.33) | CYP2B6NOS1KMT2ACNR1CNR2 | |
| SCHEMBL25740902 | 0.84 | KMT2A (0.33) | CYP2B6NOS1KMT2ACNR1CNR2 | |
| SCHEMBL25741450 | 0.84 | NOS1 (0.36) | CYP2B6NOS1KMT2ACNR1CNR2 | |
| SCHEMBL24034926 | 0.84 | NOS1 (0.37) | CYP2B6NOS1KMT2AFDPSPRCP | |
| SCHEMBL9933457 | 0.82 | PIM1 (0.36) | NOS1KMT2AFDPSPRCPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| CN-119031913-A | Purine and methods of use thereof | 奇尼塔公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-4444312-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-11479538-B2 | Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-10-25 | — | — | US | disclosed |
| CN-101066950-A | 4-amino-5-methylpyrazole derivatives and process for producing the same | SANKYO AGRO CO LTD (JP) | 2007-11-07 | — | — | CN | disclosed |
| CN-101062917-A | 4-amino-5-methylpyrazole derivatives and process for producing the same | SANKYO AGRO CO LTD (JP) | 2007-10-31 | — | — | CN | disclosed |
| CN-101062918-A | 4-amino-5-methylpyrazole derivatives and process for producing the same | SANKYO AGRO CO LTD (JP) | 2007-10-31 | — | — | CN | disclosed |
| CN-1732155-A | 4-amino-5-methylpyrazole derivatives and process for producing the same | SANKYO AGRO CO LTD (JP) | 2006-02-08 | — | — | CN | disclosed |
| EP-1580189-A1 | 4-AMINO-5-METHYLPYRAZOLE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF | Sankyo Agro Company, Limited (JP) | 2005-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | CYP2B6 3379/4885NOS1 4290/4885KMT2A 364/4885 |
| US-11479538-B2 | Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors | DGAT2, MGAT2, SLC10A1 | CYP2B6 777/4885NOS1 3935/4885KMT2A 499/4885 |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | CYP2B6 474/4885NOS1 371/4885KMT2A 919/4885 |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | CYP2B6 4186/4885NOS1 4048/4885KMT2A 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.